Study Published in the Journal of Medicinal Chemistry Demonstrates the Power of Machine Learning to Unlock New Chemistry and Biology to Treat Disease
WALTHAM, Mass. β June 11, 2020 β X-Chem, Inc., the leader in DNA-encoded small molecule library screening, and ZebiAI Therapeutics, a drug discovery company unlocking new disease targets, today announced the publication of a large prospective study to evaluate the power of machine learning (ML) to accelerate and improve the drug discovery process. The study, published in the Journal of Medicinal Chemistry, titled βMachine Learning on DNA-encoded Libraries: A New Paradigm for Hit-finding,β was conducted in collaboration with Google Accelerated Science (GAS), who developed the highly predictive ML algorithms.
X‑Chem Announces OpenDEX DNA-Encoded Library Screening
Flexible and Cost-Effective Solution for Screening Billions of Small Molecules WALTHAM, Mass.; May 11, 2021 (Business Wire) β X-Chem, the...
Focusing on building blocks and properties is the best way to design better DNA-Encoded Libraries (DELs)
It seems to be a common experience. Your new drug discovery project has accessed a DEL screen and youβre eagerly...
Protein-Protein Interactions: A Key to Precision Medicine
Protein-protein interactions (PPIs) are the foundation of life, controlling everything from cell growth and division to metabolism and signaling.1 Targeting...
Log KIAM Is the New LogD
By Johan Bartholomeus, Senior Principal Scientist, and Philippe McGee, Principal Scientist In a drug discovery project, during the hit-to-lead and...
X‑Chem and Ono Enter into Multi-Target Drug Discovery Collaboration
WALTHAM, Mass. β March 21, 2017 β X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, today announced a partnership with Ono Pharmaceutical Co., Ltd. (Ono). Under the terms of the agreement X-Chem will apply its proprietary DEXTM libraries, which contain over 120 billion small molecules, toward the discovery of new drug leads against multiple promising, high-impact oncology targets. Ono will have the option to license identified lead compounds and will be responsible for further development and commercialization of any resulting programs. X-Chem receives an upfront payment, research and licensing fees, and is eligible for additional payments linked to the successful achievement of pre-clinical and clinical development markers, as well as regulatory milestones, in addition to royalties on sales of products originating from the collaboration. No further financial terms will be disclosed.
X‑Chem’s New ReadiDELs Offer a Shorter Route to the Benefits of DEL Innovation
The last two years have seen X-Chem transform itself from a boutique DEL screening shop to an integrated drug discovery...
Truncations, Side Products and Truth in Labeling for DNA-Encoded Libraries: A Cautionary Tale
Did you ever search a library catalog, dutifully note the location of a book that is allegedly not checked out,...
ArtemisAI
Incorporate Cutting Edge AI Into Your Drug Discovery Welcome to the future of artificial intelligence (AI) in drug discovery, where...